<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337738</url>
  </required_header>
  <id_info>
    <org_study_id>TVP-1012/CCT-002</org_study_id>
    <secondary_id>U1111-1165-1364</secondary_id>
    <secondary_id>JapicCTI-152759</secondary_id>
    <nct_id>NCT02337738</nct_id>
  </id_info>
  <brief_title>A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1
      mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with
      wearing-off phenomenon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase
      2/3 study to evaluate the efficacy and safety of TVP-1012 as an add-on to levodopa in
      Japanese participants with Parkinson's disease with wearing-off phenomenon.

      The study period consisted of a 28-week trial period. The participants who fulfilled the
      inclusion criteria and did not meeting any of the exclusion criteria were enrolled, and
      randomized in a 1:1:1 ratio to the 0.5 mg of TVP-1012, the 1 mg of TVP-1012, or the placebo
      group. In each treatment group, participants received 0.5 mg of TVP-1012, 1 mg of TVP-1012,
      or placebo once daily in a double-blinded manner.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2015</start_date>
  <completion_date type="Actual">September 17, 2016</completion_date>
  <primary_completion_date type="Actual">September 17, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Daily OFF-time During Treatment Period</measure>
    <time_frame>From Baseline to Week 26</time_frame>
    <description>Reported change from baseline during treatment period which was calculated as follows: Mean for a total of 21 days, consisting of three separate 7-day periods preceding the visits at Week 6, 14 and 26 of the treatment period - Mean for the 7 days preceding the visit at the end of the run-in period. Off-time refers to times when levodopa is not working well, causing worsening symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 26 (LOCF) in Mean Daily OFF-time</measure>
    <time_frame>Baseline and Week 26 (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Total Score</measure>
    <time_frame>Baseline and Week 26 (LOCF)</time_frame>
    <description>MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part II Total Score was 0-52, with higher scores reflecting greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MDS-UPDRS Part III Total Score</measure>
    <time_frame>Baseline and Week 26 (LOCF)</time_frame>
    <description>MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part III Total Score was 0-136, with higher scores reflecting greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Score</measure>
    <time_frame>Baseline and Week 26 (LOCF)</time_frame>
    <description>PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Each Domain Score</measure>
    <time_frame>Baseline and Week 26 (LOCF)</time_frame>
    <description>PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Vital Signs Values</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAE Related to Body Weight (Weight Decreased)</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAE Related to Electrocardiograms (ECG) (Sinus Bradycardia)</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAE Related to Clinical Laboratory Tests</measure>
    <time_frame>Up to Week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>TVP-1012 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TVP-1012 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TVP-1012 1mg</intervention_name>
    <description>TVP-1012 1mg Tablets</description>
    <arm_group_label>TVP-1012 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TVP-1012 0.5mg</intervention_name>
    <description>TVP-1012 0.5mg Tablets</description>
    <arm_group_label>TVP-1012 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the opinion of the investigator or sub-investigator, the participant is capable of
             understanding and complying with protocol requirements.

          -  The participant signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          -  The participant has a diagnosis of Parkinson's disease according to the diagnostic
             criteria of the UK Parkinson's Disease Society Brain Bank.

          -  The participant has Modified Hoehn &amp; Yahr stage 2 to 4 (in the &quot;Off&quot; state) at the
             start of the run-in period.

          -  The participant has wearing off phenomenon and has been continuously receiving a
             levodopa combination drug for &gt;= 6 months prior to the start of the run-in period.

          -  The participant has been receiving a levodopa combination drug with a stable dose
             regimen (dosing frequency, at least 3 times a day) since the start of the run-in
             period.

          -  For participants receiving eantacapone concomitantly,the participant has been
             receiving entacapone with a stable dose regimen from the start of the run-in period.

          -  For participants receiving a dopamine agonist, anticholinergic drug, amantadine,
             droxidopa, istradefylline, or zonisamide concomitantly, the participant has been
             receiving those drugs with a stable dose regimen since 14 days prior to the start of
             the run-in period.

          -  The participant is an outpatient of either sex aged &gt;= 30 and &lt; 80 years at the time
             of consent.

          -  A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to use routinely adequate contraception from signing
             of informed consent to 1 month after the last dose of the investigational drug.

          -  The participant has completed patient diary for at least 4 of the 7 days preceding the
             study visit at the end of the run-in period.

          -  The participant has mean daily off-time of &gt;= 2.5 hours at the end of the run-in
             period

        Exclusion Criteria:

          -  The participant has received any investigational medication within 90 days prior to
             the start of the run-in period.

          -  The participant has received TVP-1012 in the past.

          -  The participant is a study site employee, an immediate family member, or in a
             dependent relationship with a study site employee who is involved in the conduct of
             this study (e.g., spouse, parent, child, sibling) or may consent under duress.

          -  Participant has donated 400 mL or more of his or her blood volume within 90 days prior
             to the start of the run-in period.

          -  The participant has unstable systemic disease.

          -  The participant has severe dyskinesia.

          -  The participant has Mini-Mental State Examination (MMSE) score of &lt;= 24 at the start
             of the run-in period.

          -  The participant has known or a history of schizophrenia, major or severe depression,
             or any other clinically significant psychiatric disease

          -  The participant has major depression or severe depression, or any other clinically
             significant psychiatric disease.

          -  The participant has a history of hypersensitivity or allergies to TVP-1012 (including
             any associated excipients) or selegiline.

          -  The participant has a history of clinically significant hypertension or other
             reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever,
             herring, yeast, horsebean, banana, beer or wine).

          -  The participant has a history or concurrent of drug abuse or alcohol dependence.

          -  The participant has received neurosurgical intervention for Parkinson's disease (e.g.,
             pallidotomy, thalamotomy, deep brain stimulation).

          -  The participant has received transcranial magnetic stimulation within 6 months prior
             to the start of the run-in period.

          -  The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa
             within 90 days prior to the start of the run-in period.

          -  The participant has received single agent of levodopa, any psychoneurotic agent or
             antiemetic medication of dopamine antagonist within 14 days prior to the start of the
             run-in period. However, the participant has been receiving quetiapine or domperidone
             with a stable dose regimen for &gt;= 14 days prior to the start of the run-in period may
             be included in the study.

          -  The participant is required to take any of the prohibited concomitant medications or
             treatments.

          -  If female, the participant is pregnant or lactating or intending to become pregnant
             during, or within 1 month after the last administration of study medication in this
             study; or intending to donate ova during such time period.

          -  The participant has clinically significant neurologic, cardiovascular, pulmonary,
             hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological,
             endocrine, or hematological disease.

          -  The participant has clinically significant or unstable brain or cardiovascular
             disease, such as:

               -  clinically significant arrhythmia or cardiac valvulopathy,

               -  heart failure of NYHA Class II or higher,

               -  concurrent or a history of ischemic cardiac disease within 6 months prior to the
                  start of the run-in period,

               -  concurrent or a history of clinically significant cerebrovascular disease within
                  6 months prior to the stat of the run-in period,

               -  severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic
                  blood pressure of 110 mmHg or higher),

               -  clinically significant orthostatic hypotension (including those with diastolic
                  pressure decrease of 30 mmHg or more following postural change from
                  supine/sitting position to standing position), or

               -  a history of syncope due to hypotension within 2 years prior to the stat of the
                  run-in period.

          -  The participant is required surgery or hospitalization for surgery during the study
             period.

          -  Participant has a history of cancer within 5 years prior to the start of the run-in
             period, except cervix carcinoma in situ which has completely cured.

          -  The participant has acquired immunodeficiency syndrome (AIDS) [including human
             immunodeficiency virus (HIV) carrier], or hepatitis [including viral hepatitis carrier
             such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive].
             However, the participant who has a negative result for HCV antigen or HCV-RNA can be
             included in the study.

          -  The participant has laboratory data meeting any of the following at the start of the
             run-in period:

               -  Creatinine &gt;= 2 x upper limit of normal (ULN)

               -  Total bilirubin &gt;= 2 x ULN

               -  ALT or AST &gt;= 1.5 x ULN

               -  ALP &gt;= 3 x ULN

          -  The participant has received any of the prohibited concomitant medications or
             treatments during the run-in period.

          -  The participant who, in the opinion of the investigator or sub-investigator, is
             unsuitable for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Touon</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Onoshiro</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aizuwakamatsu</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujioka</city>
        <state>Gumma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iwamizawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsukuba</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nankoku</city>
        <state>Kochi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goshi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashisonogi-gun</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joetsu</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yufu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashiosaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irima-gun</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuji</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izunokuni</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimono</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yoshinogawa</city>
        <state>Tokushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <results_first_submitted>September 15, 2017</results_first_submitted>
  <results_first_submitted_qc>October 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2019</results_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 68 investigative sites in Japan, from 27-Jan-2015 to 15-Sep-2016.</recruitment_details>
      <pre_assignment_details>Participants with diagnosis of Parkinson's disease with wearing-off phenomenon who were enrolled in run- in period (Week -2 to 0). After that, the participants who fulfilled the inclusion criteria and did not meet any of the exclusion criteria at Week -2 and Week 0 were randomized in 1:1:1 to TVP-1012 0.5 mg, TVP-1012 1 mg, or placebo at Week 0.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
        <group group_id="P2">
          <title>TVP-1012 0.5 mg</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
        <group group_id="P3">
          <title>TVP-1012 1 mg</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation (Pre-Treatment)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pretreatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation (in-Treatment)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Judgment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
        <group group_id="B2">
          <title>TVP-1012 0.5 mg</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
        <group group_id="B3">
          <title>TVP-1012 1 mg</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="129"/>
            <count group_id="B4" value="404"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="7.62"/>
                    <measurement group_id="B2" value="66.1" spread="8.74"/>
                    <measurement group_id="B3" value="65.8" spread="8.48"/>
                    <measurement group_id="B4" value="66.1" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All participants were enrolled in Japan.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Japan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.7" spread="9.61"/>
                    <measurement group_id="B2" value="157.1" spread="10.49"/>
                    <measurement group_id="B3" value="156.6" spread="8.78"/>
                    <measurement group_id="B4" value="156.8" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.30" spread="12.723"/>
                    <measurement group_id="B2" value="56.54" spread="12.545"/>
                    <measurement group_id="B3" value="54.23" spread="11.762"/>
                    <measurement group_id="B4" value="55.02" spread="12.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.99" spread="3.917"/>
                    <measurement group_id="B2" value="22.87" spread="4.049"/>
                    <measurement group_id="B3" value="21.98" spread="3.584"/>
                    <measurement group_id="B4" value="22.28" spread="3.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Current Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never Smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Timing of Study Drug Dose</title>
          <population>The number analyzed is the number of participants with data available for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="133"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Before Breakfast</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>After Breakfast</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Parkinson's Disease</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.90" spread="4.465"/>
                    <measurement group_id="B2" value="8.53" spread="4.774"/>
                    <measurement group_id="B3" value="9.49" spread="4.992"/>
                    <measurement group_id="B4" value="8.96" spread="4.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Levodopa Use</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.49" spread="4.402"/>
                    <measurement group_id="B2" value="5.94" spread="3.984"/>
                    <measurement group_id="B3" value="7.17" spread="4.800"/>
                    <measurement group_id="B4" value="6.53" spread="4.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Levodopa Total Daily Dose</title>
          <units>mg per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="399.3" spread="141.03"/>
                    <measurement group_id="B2" value="407.8" spread="134.15"/>
                    <measurement group_id="B3" value="420.7" spread="166.42"/>
                    <measurement group_id="B4" value="409.0" spread="147.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Levodopa Frequency per Day</title>
          <units>times per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="1.07"/>
                    <measurement group_id="B2" value="3.9" spread="1.32"/>
                    <measurement group_id="B3" value="4.1" spread="1.38"/>
                    <measurement group_id="B4" value="3.9" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Use of COMT Inhibitor</title>
          <description>COMT; catechol-O-methyltransferase</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had COMT Inhibitor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no COMT Inhibitor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Use of Dopamine Agonist</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had Dopamine Agonist</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="342"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no Dopamine Agonist</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Use of Amantadine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had Amantadine</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no Amantadine</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Use of Anticholinergics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had Anticholinergics</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no Anticholinergics</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Use of Droxidopa</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had Droxidopa</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no Droxidopa</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Use of Istradefylline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had Istradefylline</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="2.869"/>
                    <measurement group_id="B2" value="24" spread="2.749"/>
                    <measurement group_id="B3" value="35" spread="2.990"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no Istradefylline</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Use of Zonisamide</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had Zonisamide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="0.608"/>
                    <measurement group_id="B2" value="51" spread="0.542"/>
                    <measurement group_id="B3" value="52" spread="0.566"/>
                    <measurement group_id="B4" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no Zonisamide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Wearing Off Phenomenon</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.94" spread="2.869"/>
                    <measurement group_id="B2" value="2.89" spread="2.749"/>
                    <measurement group_id="B3" value="3.27" spread="2.990"/>
                    <measurement group_id="B4" value="3.03" spread="2.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Hoehn &amp; Yahr Stage (ON State)</title>
          <description>Modified Hoehn &amp; Yahr Stage represented severity for symptoms of Parkinson's disease progress. The Stage of Modified Hoehn &amp; Yahr were assigned from Stage 0 (Asymptomatic) to Stage 5 (Wheelchair bound or bedridden unless aided (unable to walk even if aided)). ON-state refers to periods of the day when levodopa is working well.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.44" spread="0.608"/>
                    <measurement group_id="B2" value="2.45" spread="0.542"/>
                    <measurement group_id="B3" value="2.51" spread="0.566"/>
                    <measurement group_id="B4" value="2.46" spread="0.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Hoehn &amp; Yahr Stage (OFF State)</title>
          <description>Modified Hoehn &amp; Yahr Stage represented severity for symptoms of Parkinson's disease progress. The Stage of Modified Hoehn &amp; Yahr were assigned from Stage 0 (Asymptomatic) to Stage 5 (Wheelchair bound or bedridden unless aided (unable to walk even if aided)). OFF-state refers to periods of the day when levodopa is not working well.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.22" spread="0.708"/>
                    <measurement group_id="B2" value="3.25" spread="0.674"/>
                    <measurement group_id="B3" value="3.30" spread="0.651"/>
                    <measurement group_id="B4" value="3.26" spread="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Daily OFF-time</title>
          <description>Off-time refers to times when levodopa is not working well, causing worsening symptoms.</description>
          <units>hours per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.05" spread="2.278"/>
                    <measurement group_id="B2" value="6.33" spread="2.562"/>
                    <measurement group_id="B3" value="6.12" spread="2.430"/>
                    <measurement group_id="B4" value="6.17" spread="2.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Percentage of Daily OFF-time</title>
          <units>percentage of daily off time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.86" spread="13.373"/>
                    <measurement group_id="B2" value="38.68" spread="14.278"/>
                    <measurement group_id="B3" value="36.89" spread="13.490"/>
                    <measurement group_id="B4" value="37.47" spread="13.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDS-UPDRS Part II Total Score</title>
          <description>Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part II Total Score was 0-52, with higher scores reflecting greater severity.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.0" spread="7.29"/>
                    <measurement group_id="B2" value="13.7" spread="6.65"/>
                    <measurement group_id="B3" value="14.1" spread="7.23"/>
                    <measurement group_id="B4" value="13.6" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDS-UPDRS Part III Total Score</title>
          <description>MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part III Total Score was 0-136, with higher scores reflecting greater severity.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="13.99"/>
                    <measurement group_id="B2" value="28.7" spread="13.28"/>
                    <measurement group_id="B3" value="27.5" spread="13.09"/>
                    <measurement group_id="B4" value="27.7" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PDQ-39 Summary Index</title>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="141"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="129"/>
                    <count group_id="B4" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.97" spread="13.177"/>
                    <measurement group_id="B2" value="20.94" spread="12.393"/>
                    <measurement group_id="B3" value="22.39" spread="13.115"/>
                    <measurement group_id="B4" value="21.07" spread="12.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Daily OFF-time During Treatment Period</title>
        <description>Reported change from baseline during treatment period which was calculated as follows: Mean for a total of 21 days, consisting of three separate 7-day periods preceding the visits at Week 6, 14 and 26 of the treatment period - Mean for the 7 days preceding the visit at the end of the run-in period. Off-time refers to times when levodopa is not working well, causing worsening symptoms.</description>
        <time_frame>From Baseline to Week 26</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Daily OFF-time During Treatment Period</title>
          <description>Reported change from baseline during treatment period which was calculated as follows: Mean for a total of 21 days, consisting of three separate 7-day periods preceding the visits at Week 6, 14 and 26 of the treatment period - Mean for the 7 days preceding the visit at the end of the run-in period. Off-time refers to times when levodopa is not working well, causing worsening symptoms.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>hours per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.167"/>
                    <measurement group_id="O2" value="-1.11" spread="0.174"/>
                    <measurement group_id="O3" value="-1.35" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.320</ci_lower_limit>
            <ci_upper_limit>-0.364</ci_upper_limit>
            <estimate_desc>Estimated Value was reported for the difference between TVP-1012 1mg and Placebo (TVP-1012 1mg - Placebo).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0140</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.070</ci_lower_limit>
            <ci_upper_limit>-0.122</ci_upper_limit>
            <estimate_desc>Estimated Value was reported for the difference between TVP-1012 0.5mg and Placebo (TVP-1012 0.5mg - Placebo).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 26 (LOCF) in Mean Daily OFF-time</title>
        <time_frame>Baseline and Week 26 (LOCF)</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 (LOCF) in Mean Daily OFF-time</title>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>hours per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.207"/>
                    <measurement group_id="O2" value="-0.99" spread="0.217"/>
                    <measurement group_id="O3" value="-1.40" spread="0.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Total Score</title>
        <description>MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part II Total Score was 0-52, with higher scores reflecting greater severity.</description>
        <time_frame>Baseline and Week 26 (LOCF)</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Total Score</title>
          <description>MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part II Total Score was 0-52, with higher scores reflecting greater severity.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.408"/>
                    <measurement group_id="O2" value="-0.30" spread="0.421"/>
                    <measurement group_id="O3" value="-0.30" spread="0.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MDS-UPDRS Part III Total Score</title>
        <description>MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part III Total Score was 0-136, with higher scores reflecting greater severity.</description>
        <time_frame>Baseline and Week 26 (LOCF)</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MDS-UPDRS Part III Total Score</title>
          <description>MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part III Total Score was 0-136, with higher scores reflecting greater severity.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="0.605"/>
                    <measurement group_id="O2" value="-5.24" spread="0.623"/>
                    <measurement group_id="O3" value="-5.65" spread="0.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Score</title>
        <description>PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.</description>
        <time_frame>Baseline and Week 26 (LOCF)</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Score</title>
          <description>PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="0.809"/>
                    <measurement group_id="O2" value="0.33" spread="0.829"/>
                    <measurement group_id="O3" value="-1.00" spread="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Each Domain Score</title>
        <description>PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.</description>
        <time_frame>Baseline and Week 26 (LOCF)</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Each Domain Score</title>
          <description>PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.</description>
          <population>Full Analysis Set included all randomized participants who received at least 1 dose of the study drug for the treatment period. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="1.515"/>
                    <measurement group_id="O2" value="-0.64" spread="1.552"/>
                    <measurement group_id="O3" value="-2.80" spread="1.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities of Daily Living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="1.348"/>
                    <measurement group_id="O2" value="-1.28" spread="1.382"/>
                    <measurement group_id="O3" value="-3.72" spread="1.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="1.295"/>
                    <measurement group_id="O2" value="-0.01" spread="1.329"/>
                    <measurement group_id="O3" value="-0.36" spread="1.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stigma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="1.161"/>
                    <measurement group_id="O2" value="-3.28" spread="1.190"/>
                    <measurement group_id="O3" value="-2.90" spread="1.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Support</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="1.043"/>
                    <measurement group_id="O2" value="0.60" spread="1.072"/>
                    <measurement group_id="O3" value="1.38" spread="1.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.219"/>
                    <measurement group_id="O2" value="3.15" spread="1.252"/>
                    <measurement group_id="O3" value="0.69" spread="1.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="1.107"/>
                    <measurement group_id="O2" value="1.59" spread="1.136"/>
                    <measurement group_id="O3" value="2.26" spread="1.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="1.367"/>
                    <measurement group_id="O2" value="2.36" spread="1.401"/>
                    <measurement group_id="O3" value="-0.92" spread="1.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <time_frame>Up to Week 26</time_frame>
        <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Markedly Abnormal Vital Signs Values</title>
        <time_frame>Up to Week 26</time_frame>
        <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Vital Signs Values</title>
          <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature (&lt;35.6 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature(&gt;37.7 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (&gt;180 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure(&lt;50 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure (&gt;100 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (&lt;45 bpm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse ( &gt;120 bpm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAE Related to Body Weight (Weight Decreased)</title>
        <time_frame>Up to Week 26</time_frame>
        <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAE Related to Body Weight (Weight Decreased)</title>
          <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAE Related to Electrocardiograms (ECG) (Sinus Bradycardia)</title>
        <time_frame>Up to Week 26</time_frame>
        <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAE Related to Electrocardiograms (ECG) (Sinus Bradycardia)</title>
          <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAE Related to Clinical Laboratory Tests</title>
        <time_frame>Up to Week 26</time_frame>
        <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O2">
            <title>TVP-1012 0.5 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
          <group group_id="O3">
            <title>TVP-1012 1 mg</title>
            <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAE Related to Clinical Laboratory Tests</title>
          <population>Safety Analysis set included all participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyltransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood alkaline phosphatase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine ketone body present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 26</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, one placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
        <group group_id="E2">
          <title>TVP-1012 0.5 mg</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 0.5 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
        <group group_id="E3">
          <title>TVP-1012 1 mg</title>
          <description>For 2 weeks during the run-in period, followed by 26 weeks during the treatment period, TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Oesophageal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

